Literature DB >> 18362509

Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.

H Uemura1, T Yasui, Y Miyatani, M Yamada, M Hiyoshi, K Arisawa, M Irahara.   

Abstract

OBJECTIVE: The aim of this study was to elucidate the detail profiles of circulating osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappaB ligand (sRANKL) in post-menopausal women.
METHODS: Eighty Japanese post-menopausal women were enrolled in this cross-sectional study. Circulating OPG and free fraction of sRANKL (free sRANKL), PTH, calcium and phosphorus, age, years since menopause, body mass index, bone mineral density of the vertebral bodies (LBMD) and bone turnover markers were determined in each subject.
RESULTS: In rank order correlation analysis, serum OPG concentrations had a significant positive correlation with age (r=0.291, p=0.024) and a marginal significant negative correlation with LBMD (r=-0.247, p=0.062). However they did not have correlations with LBMD or other parameters after adjustment for age. Serum free sRANKL concentrations had a significant positive correlation with age (r=0.332, p=0.010) and a significant negative correlation with LBMD (r=-0.608, p<0.001). This correlation with LBMD persisted after adjustment for age. In a multiple regression analysis with a stepwise model, the main determinants of LBMD were age and serum free sRANKL (p=0.015 and p=0.006, respectively).
CONCLUSIONS: We found the increase in circulating OPG and sRANKL with age and a robust negative correlation between circulating free sRANKL and LBMD after adjustment for age. The increase in circulating free sRANKL may reflect directly or indirectly the conditions coexistent with bone loss in post-menopausal women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362509     DOI: 10.1007/bf03345584

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 2.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.

Authors:  T Nakashima; Y Kobayashi; S Yamasaki; A Kawakami; K Eguchi; H Sasaki; H Sakai
Journal:  Biochem Biophys Res Commun       Date:  2000-09-07       Impact factor: 3.575

5.  Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

Authors:  Bo Abrahamsen; Jacob Vb Hjelmborg; Paul Kostenuik; Lis S Stilgren; Kirsten Kyvik; Stephen Adamu; Kim Brixen; Bente L Langdahl
Journal:  Bone       Date:  2005-04       Impact factor: 4.398

Review 6.  RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Authors:  Michael Schoppet; Klaus T Preissner; Lorenz C Hofbauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

7.  Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Authors:  Astrid Fahrleitner-Pammer; Harald Dobnig; Claudia Piswanger-Soelkner; Christine Bonelli; Hans-Peter Dimai; Georg Leb; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

8.  Treatment of postmenopausal osteoporosis with transdermal estrogen.

Authors:  E G Lufkin; H W Wahner; W M O'Fallon; S F Hodgson; M A Kotowicz; A W Lane; H L Judd; R H Caplan; B L Riggs
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

Review 9.  Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?

Authors:  A Dovio; V Data; A Angeli
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

10.  Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.

Authors:  L Alvarez; P Peris; N Guañabens; S Vidal; I Ros; F Pons; X Filella; A Monegal; J Muñoz-Gomez; A M Ballesta
Journal:  Arthritis Rheum       Date:  2003-03
View more
  16 in total

Review 1.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

2.  Jumping exercise preserves bone mineral density and mechanical properties in osteopenic ovariectomized rats even following established osteopenia.

Authors:  R Okubo; L S Sanada; V A Castania; M J Q Louzada; F J A de Paula; N Maffulli; A C Shimano
Journal:  Osteoporos Int       Date:  2017-01-26       Impact factor: 4.507

Review 3.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

4.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

5.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

6.  Immune changes in post-menopausal osteoporosis: the Immunos study.

Authors:  V Breuil; M Ticchioni; J Testa; C H Roux; P Ferrari; J P Breittmayer; C Albert-Sabonnadière; J Durant; F De Perreti; A Bernard; L Euller-Ziegler; G F Carle
Journal:  Osteoporos Int       Date:  2009-10-30       Impact factor: 4.507

7.  OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

Authors:  Andrea Z LaCroix; Rebecca D Jackson; Aaron Aragaki; Charles Kooperberg; Jane A Cauley; Zhao Chen; Meryl S Leboff; David Duggan; Jean Wactawski-Wende
Journal:  Bone       Date:  2013-06-02       Impact factor: 4.398

8.  Serum osteoprotegerin levels are related to height loss: the Tromsø Study.

Authors:  Lone Jørgensen; John-Bjarne Hansen; Jan Brox; Ellisiv Mathiesen; Anders Vik; Bjarne K Jacobsen
Journal:  Eur J Epidemiol       Date:  2011-02-18       Impact factor: 8.082

Review 9.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

10.  Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.

Authors:  Iwona Krela-Kaźmierczak; Marta Kaczmarek-Ryś; Aleksandra Szymczak; Michał Michalak; Marzena Skrzypczak-Zielińska; Natalia Drwęska-Matelska; Michalina Marcinkowska; Piotr Eder; Lilianna Łykowska-Szuber; Ewa Wysocka; Krzysztof Linke; Ryszard Słomski
Journal:  Calcif Tissue Int       Date:  2016-09-17       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.